Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Paolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, Caroline Robert, Vanna Chiarion-Sileni, Ana Arance, Céleste Lebbé, Inge Marie Svane, Catriona McNeil, Piotr Rutkowski, Carmen Loquai, Laurent Mortier, Omid Hamid, Lars Bastholt, Brigitte Dreno, Dirk Schadendorf, Claus Garbe, Marta Nyakas, Jean-Jacques Grob, Luc Thomas, Gabriella Liszkay, Michael Smylie, Christoph Hoeller, Virginia Ferraresi, Florent Grange, Ralf Gutzmer, Joanna Pikiel, Fareeda Hosein, Burcin Simsek, Michele Maio
Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000391; DOI: 10.1136/jitc-2019-000391